Please use this identifier to cite or link to this item:
The Change of Matrix Metalloproteinase-2, -9 and Glucocorticoid in Dogs with Mammary Gland Tumor
|關鍵字:||matrix metalloproteinase;基質金屬蛋白酵素;MMP-2;MMP-9;MGT;mammary gland;glucocorticoid;乳腺腫瘤;狗;糖皮質固醇||出版社:||獸醫學系暨研究所||引用:||Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55: 434-439, 1995. Blavier L, Lazaryev A, Dorey F, Shackleford GM, DeClerck YA. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Cancer Res 66: 2691-2699, 2006. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002. Chang SC, Chang CC, Chang TJ, Wong ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). J Am Vet Med Assoc 227: 1625-1629, 2005. Chu LL, Rutteman GR, Kong JM, Ghahremani M, Schmeing M, Misdorp W, van Garderen E, Pelletier J. Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res Treat 50: 11-25, 1998. Cockett MI, Murphy G, Birch ML, O''Connell JP, Crabbe T, Millican AT, Hart IR, Docherty AJ. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 63: 295-313, 1998. Decock J, Hendrickx W, Wildiers H, Christiaens MR, Neven P, Drijkoningen M, Paridaens R. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin Exp Metastasis 22: 495-502, 2005. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34, 2006. Duffy MJ, Maguire TM, Hill A, McDermott E, O''Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2: 252-257, 2000. Dutra AP, Granja NV, Schmitt FC, Cassali GD. c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz J Med Biol Res 37: 1673-1681, 2004. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40: 307-318, 1968. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-167, 2002. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48: 411-424, 2004. Funakoshi Y, Nakayama H, Uetsuka K, Nishimura R, Sasaki N, Doi K. Cellular proliferative and telomerase activity in canine mammary gland tumors. Vet Pathol 37: 177-183, 2000. Geho DH, Bandle RW, Clair T, Liotta LA. Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda) 20: 194-200, 2005. Hedlund CS. Surgery of the reproductive and genital systems. In: Fossum TW ed. Small animal surgery 2nd ed. Mosby, Missouri, 632-638, 2002. Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K, Lindgren A. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Vet Pathol 30: 20-27, 1993. Hirayama K, Yokota H, Onai R, Kobayashi T, Kumata T, Kihara K, Okamoto M, Saka T, Nakade T, Izumisawa Y, Taniyama H. Detection of matrix metalloproteinases in canine mammary tumors : Analysis by immunohistochemistry and zymography. J Comp pathol 127: 249-256, 2002. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89: 1817-1821, 2003. Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113: 821-823, 2003. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58: 1048-1051, 1998. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 314: 241-244, 2001. Kawamata H, Kameyama S, Kawai K, Tanaka Y, Nan L, Barch DH, Stetler-Stevenson WG, Oyasu R. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 63: 568-575, 1995. Kuvaja P, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma. Hum Pathol 37: 1316-1323, 2006. Lana SE, Ogilvie GK, Hansen RA, Powers BE, Dernell WS, Withrow SJ. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 61: 111-114, 2000. Lee CH, Kim WH, Kang MS, Kim DY, Kweon OK. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 5: 63-69, 2004. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: 5054-5059, 1991. Loukopoulos P, Mungall BA, Straw RC, Thornton JR, Robinson WF. Matrix metalloproteinase-2 and -9 involvement in canine tumors. Vet Pathol 40: 382-394, 2003. Madlener M, Parks WC, Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 242: 201-210, 1998. Misdorp W, Hart AA. Prognostic factors in canine mammary cancer. J Natl Cancer Inst 56: 779-786, 1976. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999. Patsikas MN, Karayannopoulou M, Kaldrymidoy E, Papazoglou LG, Papadopoulou PL, Tzegas SI, Tziris NE, Kaitzis DG, Dimitriadis AS, Dessiris AK. The lymph drainage of the neoplastic mammary glands in the bitch: a lymphographic study. Anat Histol Embryol 35: 228-234, 2006. Perez Alenza D, Rutteman GR, Pena L, Beynen AC, Cuesta P. Relation between habitual diet and canine mammary tumors in a case-control study. J Vet Intern Med 12: 132-139, 1998. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remacle A, Stetler-Stevenson WG, Birembaut P, Foidart M. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 424: 641-645, 1994. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106: 745-751, 2003. Rutteman GR. Contraceptive steroid and the mammary gland: Is there hazard. Breast Cancer Res Treat 23: 29-41, 1992. Rutteman GR, Kirpensteijn J. Tumours of mammary glands. In: Dobson JM, Lascelles BD, eds. BSAVA manual of canine and feline oncology 2nd ed. BSAVA, Gloucester, 234-242, 2003. Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 43: 1249-1261, 1969. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61: 237-242, 2001. Sorenmo KU, Shofer FS, Goldschmidt MH. Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J Vet Intern Med 14: 266-270, 2000. Tang Y, Kesavan P, Nakada MT, Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2: 73-80, 2004. Tarlton JF, Vickery CJ, Leaper DJ, Bailey AJ. Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase-9. Br J Dermatol 137: 506-516, 1997. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 80: 1529-1537, 1997. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13: 2054-2060, 2007. Yamagami T, Kobayashi T, Takahashi K, Sugiyama M. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. J Vet Med Sci 58: 1079-1083, 1996. Yokota H, Kumata T, Taketaba S, Kobayashi T, Moue H, Taniyama H, Hirayama K, Kagawa Y, Itoh N, Fujita O, Nakade T, Yuasa A. High expression of 92 kDa type IV collagenase (matrix metalloproteinase-9) in canine mammary adenocarcinoma. Biochim Biophys Acta 1568: 7-12, 2001. Zucker S, Cao J. Detection of activated, TIMP-free MMPs. Chem Biol 13: 347-349, 2006. Zucker S, Lysik RM, Zarrabi MH, Moll U. Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140-146, 1993.||摘要:||
母犬的乳腺腫瘤（mammary gland tumor, MGT）為臨床上最常見的腫瘤之ㄧ，其中約有40~50％為惡性腫瘤。術後腫瘤的復發及轉移一直是造成病犬死亡的重要原因，然而，現今獸醫臨床上的診斷工具對於腫瘤復發或轉移的早期並不敏感，容易對於患犬的病情造成誤判。基質金屬蛋白酵素（matrix metalloproteinase, MMP）為一群可分解細胞外基質（extracellular matrix, ECM）成份的酵素，它們對於ECM的分解被認為與腫瘤的侵入及轉移相關。糖皮質固醇（glucocorticoids, GC）在乳腺的發育及分化上扮演著重要的角色，而其也可能參與了乳腺的腫瘤化過程。為了了解MMP-2、MMP-9及GC在乳腺腫瘤犬隻之變化情形，我們收集了經中興大學獸醫教學醫院小動物外科門診診斷為MGT的病例，以gelatin zymography分析MMP-2與MMP-9在腫瘤組織、周圍正常乳腺組織及血漿樣本中活性的變化情形，並以enzyme linked fluorescent assay分析GC在腫瘤組織及周圍正常乳腺組織中濃度的變化。從實驗結果中發現，MMP-2與MMP-9活性在腫瘤組織中皆顯著的高於周圍正常組織，血漿MMP-2與MMP-9活性於MGT病犬也皆顯著高於非腫瘤對照組。血漿MMP-9活性會隨著乳腺腫瘤的移除而下降，但MMP-2並沒有相同的趨勢。在進一步的分析中，血漿MMP-9活性的變化與腫瘤組織中MMP-9活性呈正相關。在GC濃度的分析方面，腫瘤組織及正常乳腺組織間並沒有顯著性差異。根據以上結果，我們發現病犬體內MMP-2與MMP-9活性的變化與腫瘤的惡性程度相關，而血漿MMP-9活性的變化有潛力成為患犬術後病情追蹤及預後評估的指標因子。
Mammary gland tumor (MGT) is one of the most common neoplasias in female dogs, having approximately 40~50% of them considered malignant. Tumor recurrence and metastasis are the most important factors to cause patient death after surgery. However, the diagnostic tools in veterinary practice up to now are not sensitive in early stage of tumor recurrence and metastasis. Matrix metalloproteinase (MMP) family is thought to be responsible for the accelerated breakdown of extra-cellular matrix (ECM) associated with tumor invasion and metastasis. Besides, glucocorticoids (GC) has been shown to play important roles in mammary development and differentiation, and probably implicated in mammary tumorigenesis. In order to understand the change of MMP-2, MMP-9 and GC in dogs with MGT, the activity of MMP-2 and MMP-9 in plasma samples, MGT tissues and normal mammary gland tissues near by were evaluated by gelatin zymography, and the concentration of GC in MGT tissues and normal mammary gland tissues near by was determined by enzyme linked fluorescent assay. The levels of MMP-2 and MMP-9 were significantly higher in tumor tissues than those in normal gland tissues. Plasma MMP-9 levels in malignant cases were higher than that in benign and nontumor cases. Likewise, plasma MMP-2 levels in most MGT cases were higher than nontumor cases. The level of plasma MMP-9 decreased after surgery, but MMP-2 did not. Further analysis indicated that plasma MMP-9 levels were correlated with tumor tissue MMP-9 levels. GC concentration in MGT tissues has no significantly difference from normal gland tissues. Our results indicated that the change of MMP-2 and MMP-9 levels are associated with tumor malignancy, and plasma MMP-9 activity may become a potential marker both in the follow-up and in the prognosis of canine MGT patients.
|Appears in Collections:||獸醫學系所|
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.